Exome Sequencing and Congenital Heart Disease in Sub-Saharan Africa
BACKGROUND: Congenital heart disease (CHD) is the most common birth defect and affects roughly 1% of the global population. There have been many large CHD sequencing projects in developing countries but none in sub-Saharan Africa. In this exome sequencing study, we recruited families from Lagos, Nigeria, affected by structural heart disease.
METHODS: Ninety-eight participants with CHD and an average age of 3.6 years were recruited from Lagos, Nigeria. Exome sequencing was performed on probands and parents when available. For genes of high interest, we conducted functional studies in Drosophila using a cardiac-specific RNA interference-based gene silencing system.
RESULTS: The 3 most common CHDs were tetralogy of Fallot (20%), isolated ventricular septal defect (14%), and transposition of the great arteries (8%). Ten percent of the cohort had pathogenic or likely pathogenic variants in genes known to cause CHD. In 64 complete trios, we found 34 de novo variants that were not present in the African population in the Genome Aggregation Database (v3). Nineteen loss of function variants were identified using the genome-wide distribution of selection effects for heterozygous protein-truncating variants (shet). Nine genes caused a significant mortality when silenced in the Drosophila heart, including 4 novel disease genes not previously associated with CHD (UBB, EIF4G3, SREBF1, and METTL23).
CONCLUSIONS: This study identifies novel candidate genes and variants for CHD and facilitates comparisons with previous CHD sequencing studies in predominantly European cohorts. The study represents an important first step in genomic studies of CHD in understudied populations. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01952171.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Circulation. Genomic and precision medicine - 14(2021), 1 vom: 27. Feb., Seite e003108 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ekure, Ekanem N [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.01.2022 Date Revised 07.12.2022 published: Print-Electronic ClinicalTrials.gov: NCT01952171 Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCGEN.120.003108 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320120821 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320120821 | ||
| 003 | DE-627 | ||
| 005 | 20231225172913.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCGEN.120.003108 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1067.xml |
| 035 | |a (DE-627)NLM320120821 | ||
| 035 | |a (NLM)33448881 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ekure, Ekanem N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exome Sequencing and Congenital Heart Disease in Sub-Saharan Africa |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT01952171 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Congenital heart disease (CHD) is the most common birth defect and affects roughly 1% of the global population. There have been many large CHD sequencing projects in developing countries but none in sub-Saharan Africa. In this exome sequencing study, we recruited families from Lagos, Nigeria, affected by structural heart disease | ||
| 520 | |a METHODS: Ninety-eight participants with CHD and an average age of 3.6 years were recruited from Lagos, Nigeria. Exome sequencing was performed on probands and parents when available. For genes of high interest, we conducted functional studies in Drosophila using a cardiac-specific RNA interference-based gene silencing system | ||
| 520 | |a RESULTS: The 3 most common CHDs were tetralogy of Fallot (20%), isolated ventricular septal defect (14%), and transposition of the great arteries (8%). Ten percent of the cohort had pathogenic or likely pathogenic variants in genes known to cause CHD. In 64 complete trios, we found 34 de novo variants that were not present in the African population in the Genome Aggregation Database (v3). Nineteen loss of function variants were identified using the genome-wide distribution of selection effects for heterozygous protein-truncating variants (shet). Nine genes caused a significant mortality when silenced in the Drosophila heart, including 4 novel disease genes not previously associated with CHD (UBB, EIF4G3, SREBF1, and METTL23) | ||
| 520 | |a CONCLUSIONS: This study identifies novel candidate genes and variants for CHD and facilitates comparisons with previous CHD sequencing studies in predominantly European cohorts. The study represents an important first step in genomic studies of CHD in understudied populations. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01952171 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a Drosophila | |
| 650 | 4 | |a Nigeria | |
| 650 | 4 | |a Tetralogy of Fallot | |
| 650 | 4 | |a exome | |
| 650 | 4 | |a heart disease | |
| 650 | 7 | |a Eif4g3 protein, mouse |2 NLM | |
| 650 | 7 | |a Eukaryotic Initiation Factor-4G |2 NLM | |
| 650 | 7 | |a UBB protein, human |2 NLM | |
| 650 | 7 | |a Ubiquitin |2 NLM | |
| 700 | 1 | |a Adeyemo, Adebowale |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hanhan |e verfasserin |4 aut | |
| 700 | 1 | |a Sokunbi, Ogochukwu |e verfasserin |4 aut | |
| 700 | 1 | |a Kalu, Nnenna |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez, Ariel F |e verfasserin |4 aut | |
| 700 | 1 | |a Owosela, Babajide |e verfasserin |4 aut | |
| 700 | 1 | |a Tekendo-Ngongang, Cedrik |e verfasserin |4 aut | |
| 700 | 1 | |a Addissie, Yonit A |e verfasserin |4 aut | |
| 700 | 1 | |a Olusegun-Joseph, Akinsanya |e verfasserin |4 aut | |
| 700 | 1 | |a Ikebudu, Desmond |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Seth I |e verfasserin |4 aut | |
| 700 | 1 | |a Muenke, Maximilian |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Zhe |e verfasserin |4 aut | |
| 700 | 1 | |a Kruszka, Paul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation. Genomic and precision medicine |d 2018 |g 14(2021), 1 vom: 27. Feb., Seite e003108 |w (DE-627)NLM280989210 |x 2574-8300 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g number:1 |g day:27 |g month:02 |g pages:e003108 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCGEN.120.003108 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 1 |b 27 |c 02 |h e003108 | ||